Organisation › Details

Rainier Therapeutics Inc.

Rainier Therapeutics, Inc. is a privately-held, clinical stage biotechnology company developing a targeted biologic for the potential treatment of metastatic and early stage bladder cancer, an area of high unmet need. The company’s antibody, vofatamab (B-701) is focused specifically on the fibroblast growth factor receptor 3 (FGFR3), a known driver of bladder and other cancers. Vofatamab is the most advanced targeted biologic specific for FGFR3 known in clinical development. Rainier Therapeutics has ongoing Phase 1b and Phase 2 clinical studies of vofatamab in metastatic bladder cancer – the Fierce 21 and Fierce 22 studies. In addition, Rainier Therapeutics plans to study vofatamab in early stage bladder cancer – the Fierce 23 trial. The Fierce 21 trial is evaluating vofatamab alone and in combination with docetaxel versus docetaxel alone to determine safety and efficacy in the treatment of FGFR3 mutant/fusion patients with locally advanced or metastatic bladder cancer who have relapsed after, or are refractory to, at least one prior line of chemotherapy. For more on this trial, visit (NCT0240542). The Fierce 22 trial is evaluating vofatamab in combination with pembrolizumab, an immune checkpoint inhibitor, to determine safety, tolerability and efficacy in the treatment of patients with locally advanced or metastatic bladder cancer, who have progressed following platinumbased chemotherapy and who have not received prior immune checkpoint inhibitor therapy. For more on this trial, visit (NCT03123055). The Fierce 23 trial will evaluate vofatamab monotherapy in non-muscle invasive bladder cancer (NMIBC). This trial is planned to start in 2019. *


Period Start 2018-11-27 renamed
  Predecessor BioClin Therapeutics Inc.
Products Industry MAb
  Industry 2 vofatamab (B-701)
Person Person Lau, Stephen (BioClin Therapeutics –201809 Founding CEO STEPPED DOWN 9/18)
  Street 1040 Davis Street
  City 94577 San Leandro, CA
  Tel +1-925-413-6140
    Address record changed: 2018-12-07
Basic data Employees n. a.
    * Document for �About Section�: Rainier Therapeutics, Inc.. (11/27/18). "Press Release: BioClin Therapeutics Announces Name Change to Rainier Therapeutics". San Leandro, CA.
Record changed: 2018-12-07


Picture [LSUS] – The Business Web Portal 650x112px

More documents for Rainier Therapeutics Inc.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] – Putting Information into Context 600x60px

» top